CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
A few days ago, our Roche leadership team had the exciting opportunity to meet with NVIDIA at their headquarters in Santa Clara. Bringing science and #technology together has always been the superpower of biomedical breakthroughs. This is why we are thrilled about our strategic research partnership with NVIDIA. The collaboration between Roche and NVIDIA is all about combining our key strengths: we will couple our #artificialintelligence capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development. I couldn’t agree more with Jensen Huang: “The greatest impact of generative #AI is to revolutionise the life science and #healthcare industry.” I am confident that together we will dramatically accelerate the pace of drug discovery and development for millions of patients around the world. Thanks for having us, Team NVIDIA! We look forward to bringing research to the next level.
John F Palma
4w
This combination is energizing. Make it count. Patients are waiting for you to do what is next!
Michael Lipari
1mo
There needs to be an equal emphasis on the back of the coin (patient journey and outcomes) as much as there is on the front of the coin (drug development and discovery) to have a true linear picture of the landscape.
The complexity of the human genome and differential expression of genes interacting with drugs, the gut Microbiome, pathogens, environmental changes are processes we barely understand even though the genome was sequenced around 2002. Achieving the goals of personalized and / or precision medicine, understanding differences in response to drugs & adverse drug reactions reactions requires a wholistic approach that will need data integration & analysis using AI. This is a great collaboration & AI should greatly enhance patient selection, clinical trials and ensure better therapeutic efficacy. Congratulations
This partnership is so clear with it's benefits and goals regarding the business apsect, which perhaps should've happened sooner, since it will take time to work on bringing the exact results needed - The other part regarding patient care, education and all other human related topics would probably need double that
It's an exciting time for the HCLS industry! The advancements in technology, especially in AI, are paving the way for concrete outcomes that can significantly improve healthcare and life sciences. The pace of innovation will depend on the ease of use and security of these technologies for widespread adoption. Looking forward to seeing the positive impact these innovations will bring.
Drug discovery effort is the cash cow … I get the excitement … but as many have pointed out patient care, education and journey needs emphasis
We need to use #AI diagnostic and treatment algorithms to bring personalized solutions to patients and go beyond guidelines. In fact, the one “size fits all” approach in medicine is not beneficial for patients nor for healthcare care systems, both searching for specific and sustainable care. Additionally, obsolete guidelines impair the independency and agility needed by medical doctors to choose for the best possible solutions for the singular patients in front of them; decisions which should be taken based on latest scientific discoveries and not guidelines which are based on medical knowledge which is at least 10 years outdated.
Love this partnership! The perfect match for science, data, and rapidly advancing technology and power in AI.
Rory Kelleher
1mo
Thank you Thomas Schinecker and the Roche leadership team for spending time with us. Looking forward to making great strides together to do things we couldn’t do alone. We’re honored to support the work of brilliant Roche scientists and technologists.
Experienced Medical Doctor and leader with a long experience in medical laboratory, industrial R&D of medical diagnostics, quality and regulatory affairs, project sponsoring, mentoring and organizing cooperations.
1moAn obvious idea with the potential. It is certainly easy for anyone to understand that AI can improve the quality of clinical care. However, there is still a long way to go to achieve this goal: The exact connection between data input and results output is a black box in AI. We don't really understand what happens there and why. This is especially true when AI delivers grotesque and completely unpredictable results. From the point of view of the notified and other regulatory bodies, this would probably be the perfect nightmare. Nobody would justify entrusting an unpredictable and inexplicably erratic system with our most precious asset: human health. At a technical level, traceability and reproducibility are the parameters from which medical AI is still miles away. The reason for this lies deep in the fundamental principle of so-called AI. It will be interesting to see how this challenge is solved in the future. Only then would the way be paved for serious application in a medical context.